Mostrar el registro sencillo del ítem
Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats
dc.contributor.author | Rodríguez Sojo, María Jesús | |
dc.contributor.author | García García, Jorge | |
dc.contributor.author | Ruiz Malagón, Antonio Jesús | |
dc.contributor.author | Díez Echave, Patricia | |
dc.contributor.author | Hidalgo García, Laura | |
dc.contributor.author | Molina Tijeras, José Alberto | |
dc.contributor.author | González Lozano, Elena | |
dc.contributor.author | López Escánez, Laura | |
dc.contributor.author | Rodríguez Cabezas, María Elena | |
dc.contributor.author | Rodríguez Sánchez, María José | |
dc.contributor.author | Rodríguez Nogales, Alba | |
dc.contributor.author | Mediavilla García, Palmira Cristina | |
dc.contributor.author | Gálvez Peralta, Julio Juan | |
dc.date.accessioned | 2023-02-09T11:40:21Z | |
dc.date.available | 2023-02-09T11:40:21Z | |
dc.date.issued | 2022-12-21 | |
dc.identifier.citation | Rodríguez-Sojo, M.J... [et al.]. Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats. Nutrients 2023, 15, 24. [https://doi.org/10.3390/nu15010024] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/79789 | |
dc.description.abstract | Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to restore altered immune responses, in association with microbiome modulation in different pathological conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716 in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum CECT5716 (109 CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients. | es_ES |
dc.description.sponsorship | Junta de Andalucia A-CTS-447-UGR18 CTS 164 | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III | es_ES |
dc.description.sponsorship | European Commission PI19/01058 PI20/01447 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | IBS rat model | es_ES |
dc.subject | Probiotic | es_ES |
dc.subject | Limosilactobacillus fermentum CECT5716 | es_ES |
dc.subject | Intestine anti-inflammatory activity | es_ES |
dc.subject | Visceral analgesia | es_ES |
dc.title | Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/nu15010024 | |
dc.type.hasVersion | VoR | es_ES |